Industry Perceptions Meet FDA Reality In AdvaMed/Lewin Survey Of 81 Firms
This article was originally published in The Gray Sheet
Respondents to 1AdvaMed's first "State of the Medical Technology Industry" survey are holding that "elapsed development times" associated with PMA devices are on the rise, despite FDA data showing shortened or static review times
You may also be interested in...
CDRH's Office of Device Evaluation began fiscal 2003 with six fewer medical officers and three fewer scientific reviewers than in the previous year, according to the 1ODE's FY 2002 annual report
Updated guidelines on properly billing CMS for blood products and services will soon be available to hospitals from the American Association of Blood Banks, the industry group announced Oct. 15
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.